Bilateral Atypical Femur Fracture after Prolonged Use of Alendronate - A Case Report

Abstract
The use of bisphosphonates is among the most agreed upon and widespread therapies for osteoporosis control, with statistically confirmed results showing a decrease in bone resorption. However, there are significant reports of atypical femoral fractures observed in patients with long-term therapy. This study reports a bilateral femoral fracture in a patient after 7 years of treatment with Alendronate.

Keywords: Atypical femoral fractures; Alendronate; Biphosphonate

Introduction
Osteoporosis is an increasingly frequent problem among developed populations due to the longer life expectancy we experience nowadays. Anti-resorptive drugs, such as bisphosphonates, are among the most frequently used pharmaceutical treatments for osteoporosis [1]. It is agreed upon that the absolute number of vertebral and non-vertebral fractures decreases greatly with this therapy [1]. However, paradoxically, attention is brought to the increased number of atypical femoral fractures associated with low-energy trauma after long-term bisphosphonate treatment, alendronate being the most commonly used. The time taken for a significant increase in atypical fractures associated with alendronate to occur is not yet clear, but some data suggest 5 years [2], although there are reports of fractures following an even shorter duration of therapy [2-17]. The explanation consists of excessive suppression of osteoclastic activity and a consequent decrease in bone remodelling [2-5].

Case Report
We report a case of bilateral femoral fracture in a patient after 7 years of treatment with alendronate at a dose of 70 mg weekly. The patient was a 67 y.o. female with no history of any comorbidity such as diabetes, alcohol abuse, smoking, chronic use of glucocorticoids or others. She fell from her own height in March 2014, resulting in a transverse femoral shaft fracture of the left femur (Figure 1A), treated with a blocked anterograde intramedullary nail (Figure 1B & 1C). In June 2016, she suffered a contralateral short oblique femoral fracture with no history of direct trauma, presumably with a torsional mechanism - rotation around the body axis (Figure 2A). The treatment of choice was also a blocked anterograde intramedullary nail (Figures 2B & 2C). We can observe in Figures 1 & 2 the absence of compromised trabecular bone or thinning of cortical bone, corroborating the probable pathophysiology behind bisphosphonate-associated fractures - decreased bone remodelling - and not osteopenia/osteoporosis.

Discussion
The use of bisphosphonates in the treatment of osteoporosis has wide scientific support in the literature, with benefits overcoming the risks even with a treatment period longer than 10 years [4,5]. However, therapy longer than 5 years and poor
adherence to treatment are associated with a higher number of atypical femoral fractures. When analysed in the context of all femoral shaft fractures, atypical fractures may be responsible for up to 50% of them [7], depending on the population studied. Bilateral commitment is described in up to 30% of these patients, especially with a treatment period longer than 3 years [12,16]. Moreover, shaft fractures are more frequent than subtrochanteric fractures in patients older than 50 years [6,12,14]. The prevalence of female patients with femoral fractures - due to the increased incidence of osteoporosis is notable, especially those with atypical patterns, which are responsible for up to 95% of cases in this group of patients [7]. The most accepted ethiopathogenic is excessive suppression of osteoclastic activity and a consequent decrease in bone remodelling, leading to cortical hypermineralization, increased rigidity and a subsequent decrease in flexibility and resistance [2-5]. Radiographic findings are thickened cortical bone and complete transverse and short-oblique non-comminuted fractures comprising mostly the subtrochanteric region and the diaphysis [9]. There are also reports of impacted or incomplete fractures - occurring in approximately 10% of cases [7] - without history of trauma, which can make the diagnosis difficult. In these cases is important to obtain contralateral radiographs and other complementary exams, such as CT and MRI scans, to adequately diagnose and stage the lesion [10]. These cases require the suspension of bisphosphonates and maintenance of vitamin D and calcium supplementation combined with prophylactic surgical treatment [11,12].

Conclusion

As possible measures to prevent atypical femoral fractures in patients treated with bisphosphonates, we recommend orientation regarding treatment adherence, periodical medical consultations and limiting the use of bisphosphonates to a maximum of 5 years [16]. Once the fracture is stabilised, we suggest discontinuation of treatment and proper fixation of the fracture. Considering the high incidence of bilateral fractures, it is necessary to give special attention to the contralateral femur to identify adequate candidates for prophylactic surgery.

Acknowledgment

None.

Conflict of Interest

None.

References


Bilateral Atypical Femur Fracture after Prolonged Use of Alendronate - A Case Report